常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.53/-4.26
|
|
企业价值
606.32M
|
| 资产负债 |
|
每股账面净值
6.46
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
37.00K
|
|
每股收益
0.04
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/15 21:11 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |

10.79 
